Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day
Vertex Pharmaceuticals Inc. closed $106.51 short of its 52-week high ($519.88), which the company reached on November 8th.
Vertex Pharmaceuticals Incorporated (VRTX) Slid due to Setbacks In Clinical Trials
ClearBridge Investments, an investment management company, released its “ClearBridge Growth Strategy” fourth quarter 2024 ...
Vertex Pharmaceuticals Incorporated (VRTX) CEO Reshma Kewalramani Hosts 43rd Annual J.P. Morgan Healthcare Conference (Transcript)
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) 43rd Annual J.P. Morgan Healthcare Conference January 13, 2025 10:30 AM ETCompany ParticipantsDr.
Truist Financial Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX)
In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report). The ...
Citi Sticks to Its Buy Rating for Vertex Pharmaceuticals (VRTX)
Citi analyst Geoff Meacham maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price target of ...
Zacks.com on MSN3d
Vertex Pharmaceuticals (VRTX) Stock Moves -0.62%: What You Should Know
Vertex Pharmaceuticals (VRTX) closed at $409.56 in the latest trading session, marking a -0.62% move from the prior day.
International Assets Investment Management LLC Lowers Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
International Assets Investment Management LLC lowered its position in shares of Vertex Pharmaceuticals Incorporated ...
ORG Partners LLC Has $41,000 Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
ORG Partners LLC boosted its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 108.2% ...
Vertex Grapples With Bearish Chart As Death Cross Emerges
Vertex Pharmaceuticals (VRTX) is facing technical challenges, with its stock forming a Death Cross and down 15% in 6 months.
An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 42% Undervalued
An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 42% Undervalued Vertex Pharmaceuticals' estimated fair value is US$708 based on 2 Stage Free Cash Flow to ...